IRIDEX CORPIRIXEarnings & Financial Report
IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.
Revenue
$11.9M
Gross Profit
$5.1M
Operating Profit
$-205.0K
Net Profit
$-1.7M
Gross Margin
42.5%
Operating Margin
-1.7%
Net Margin
-14.2%
YoY Growth
1.1%
EPS
$-0.10
IRIDEX CORP Q1 FY2025 Financial Summary
IRIDEX CORP reported revenue of $11.9M (up 1.1% YoY) for Q1 FY2025, with a net profit of $-1.7M (up 51.3% YoY) (-14.2% margin). Cost of goods sold was $6.8M, operating expenses totaled $5.3M.
Key Financial Metrics
| Total Revenue | $11.9M |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | 42.5% |
| Operating Margin | -1.7% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
IRIDEX CORP Q1 FY2025 revenue of $11.9M breaks down across 3 segments, led by Retina at $6.6M (55.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Retina | $6.6M | 55.9% |
| Cyclo G Six | $3.2M | 26.7% |
| Other | $2.1M | 17.4% |
IRIDEX CORP Revenue by Segment — Quarterly Trend
IRIDEX CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Retina and Cyclo G Six) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Retina | — | $6.7M | $8.0M | $6.6M |
| Cyclo G Six | — | — | $3.3M | $3.2M |
| Other | — | $2.2M | $2.2M | $2.1M |
IRIDEX CORP Annual Revenue by Year
IRIDEX CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $52.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $52.7M |
| 2024 | $48.7M |
| 2023 | $51.9M |
| 2022 | $57.0M |
| 2021 | $53.9M |
IRIDEX CORP Quarterly Revenue & Net Profit History
IRIDEX CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $14.7M | -69.7% | N/A | N/A |
| Q3 FY2025 | $12.5M | +7.8% | $-1.6M | -12.6% |
| Q2 FY2025 | $13.6M | +7.4% | $-994.0K | -7.3% |
| Q1 FY2025 | $11.9M | +1.1% | $-1.7M | -14.2% |
| Q4 FY2024 | $12.7M | +1.9% | $-834.0K | -6.6% |
| Q3 FY2024 | $11.6M | -9.9% | $-1.9M | -16.7% |
| Q2 FY2024 | $12.6M | -1.7% | $-2.7M | -21.2% |
| Q1 FY2024 | $11.8M | -14.2% | $-3.5M | -29.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.8M | $12.6M | $11.6M | $12.7M | $11.9M | $13.6M | $12.5M | $14.7M |
| YoY Growth | -14.2% | -1.7% | -9.9% | 1.9% | 1.1% | 7.4% | 7.8% | -69.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $34.1M | $31.2M | $30.2M | $29.1M | $34.2M | $31.6M | $28.4M | $29.2M |
| Liabilities | $27.6M | $27.0M | $27.5M | $27.0M | $27.4M | $25.5M | $23.7M | $24.2M |
| Equity | $6.5M | $4.2M | $2.6M | $2.1M | $852000 | $6.1M | $4.7M | N/A |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-1.3M | $-3.1M | $-1.2M | $-1.1M | $-397000 | $-1.2M |